Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various
cancers. There is significant variation in clinical response to radiotherapy with or without …

Background Radical surgery via total mesorectal excision might not be the optimal first-line
treatment for early-stage rectal cancer. An organ-preserving strategy with selective total …

Colorectal cancer remains a significant cause of morbidity and mortality, even despite
curative treatment. A significant proportion of patients present emergently and have poorer …

Aim Organ‐saving treatment for early‐stage rectal cancer can reduce patient‐reported side
effects compared to standard total mesorectal excision (TME) and preserve quality of life. An …

Management of colorectal cancer | The BMJ Skip to main content Intended for healthcare
professionals Access provided by Google Indexer Subscribe My Account My email alerts BMA …

Objectives Partial or total resistance to preoperative chemoradiotherapy occurs in more than
half of locally advanced rectal cancer patients. Several novel or repurposed drugs have …

Background Older patients with early-stage rectal cancer are under-represented in clinical
trials and, therefore, little high-quality data are available to guide treatment in this patient …

Introduction Physicians must share decisions and choose personalised treatments
regarding patients´ beliefs and values. Objective To analyse the quality of the …

Aim A 'watch and wait'(W&W) strategy after neoadjuvant long‐course chemoradiotherapy
(NACRT) remains controversial. Whilst encouraging short‐term data exist, the strategy will …

Introduction Early rectal cancers are increasingly diagnosed through screening programmes
and are often treated using local excision (LE). In the case of adverse pathological features …